Contineum Therapeutics (NASDAQ:CTNM) just reported results for the second quarter of 2024.
- Contineum Therapeutics reported earnings per share of -39 cents. This was below the analyst estimate for EPS of -35 cents.
- The company did not report any revenue for the quarter.